StockNews.AI
BIOA
StockNews.AI
16 hrs

BIOAGE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

1. Bragar Eagel & Squire investigating claims against BioAge Labs for fiduciary duty breaches. 2. Class action filed after discontinuation of azelaprag trial due to safety concerns. 3. BioAge's share price plummeted from $20.09 to $4.65 following trial news.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The significant drop in stock price due to safety concerns indicates investor distrust. Historical precedents show similar issues can severely undermine a biotech's valuation.

How important is it?

The article directly discusses significant legal issues impacting BioAge and its valuation.

Why Short Term?

Immediate investor reactions are evident from the stock's price drop. However, long-term effects depend on company responses to the legal challenge.

Related Companies

BIOA
NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against BioAge Labs, Inc. (NASDAQ: BIOA) on behalf of long-term stockholders following a class action complaint that was filed against BioAge on January 7, 2024 with a Class Period pursuant and/or traceable to BioAge’s registration statement for the initial public offering held on or about September 26, 2024. Our investigation concerns whether the board of directors of BioAge have breached their fiduciary duties to the company. Details: According to the complaint, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 trial for azelaprag, its lead product candidate, citing safety concerns over elevated liver transaminase levels in participants. This came as a surprise because, at the time of its IPO less than three months earlier, BioAge highlighted azelaprag's potential in patients undergoing obesity therapy with incretin drugs.Following this news, BioAge’s stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024. Next Steps: If you are a long-term stockholder of BioAge, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, P.C.Brandon Walker, Esq.Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com

Related News